PK/PD of Caspofungin in Children Severe Infection

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age3-18
SponsorChildren's Hospital of Fudan University

About this trial

Caspofungin is an anti-fungal drug mainly metabolized by the liver. The pathophysiological status of children with severe infection will affect the metabolism of caspofungin in the body especially in the case of liver dysfunction. There is little metabolism of caspofungin through the kidney and continuous renal replacement therapy and renal function have little influence on the pharmacokinetics of caspofungin. The study aim to investigate PK/PD of caspofungin in children with specific pathophysiological conditions, such as liver insufficiency, hypoproteinemia, ECMO treatment, or sepsis.

Eligibility criteria

Qualifiers

Children receiving caspofungin in pediatric intensive care unit

Disqualifiers

No Informed Consent signed Participate in other clinical trials

Trial design

Treatments tested in this trial

  • Caspofungin

Treatment groups

60 Participants
are divided into 1 treatment group